» Articles » PMID: 31706267

Integrated Transcriptomic Analysis Reveals Hub Genes Involved in Diagnosis and Prognosis of Pancreatic Cancer

Overview
Journal Mol Med
Publisher Biomed Central
Date 2019 Nov 11
PMID 31706267
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The hunt for the molecular markers with specificity and sensitivity has been a hot area for the tumor treatment. Due to the poor diagnosis and prognosis of pancreatic cancer (PC), the excision rate is often low, which makes it more urgent to find the ideal tumor markers.

Methods: Robust Rank Aggreg (RRA) methods was firstly applied to identify the differentially expressed genes (DEGs) between PC tissues and normal tissues from GSE28735, GSE15471, GSE16515, and GSE101448. Among these DEGs, the highly correlated genes were clustered using WGCNA analysis. The co-expression networks and molecular complex detection (MCODE) Cytoscape app were then performed to find the sub-clusters and confirm 35 candidate genes. For these genes, least absolute shrinkage and selection operator (lasso) regression model was applied and validated to build a diagnostic risk score model. Cox proportional hazard regression analysis was used and validated to build a prognostic model.

Results: Based on integrated transcriptomic analysis, we identified a 19 gene module (SYCN, PNLIPRP1, CAP2, GNMT, MAT1A, ABAT, GPT2, ADHFE1, PHGDH, PSAT1, ERP27, PDIA2, MT1H, COMP, COL5A2, FN1, COL1A2, FAP and POSTN) as a specific predictive signature for the diagnosis of PC. Based on the two consideration, accuracy and feasibility, we simplified the diagnostic risk model as a four-gene model: 0.3034*log(MAT1A)-0.1526*log(MT1H) + 0.4645*log(FN1) -0.2244*log(FAP), log(gene count). Besides, a four-hub gene module was also identified as prognostic model = - 1.400*log(CEL) + 1.321*log(CPA1) + 0.454*log(POSTN) + 1.011*log(PM20D1), log(gene count).

Conclusion: Integrated transcriptomic analysis identifies two four-hub gene modules as specific predictive signatures for the diagnosis and prognosis of PC, which may bring new sight for the clinical practice of PC.

Citing Articles

Identification of potential biomarkers for lung cancer using integrated bioinformatics and machine learning approaches.

Rabby M, Islam M, Kumar S, Maniruzzaman M, Hasan M, Tomioka Y PLoS One. 2025; 20(2):e0317296.

PMID: 40014586 PMC: 11867339. DOI: 10.1371/journal.pone.0317296.


Machine learning-based prediction of distant metastasis risk in invasive ductal carcinoma of the breast.

Dong J, Lei R, Ma F, Yu L, Wang L, Xu S PLoS One. 2025; 20(2):e0310410.

PMID: 40009584 PMC: 11864521. DOI: 10.1371/journal.pone.0310410.


Integrative multi-omics analysis reveals the role of toll-like receptor signaling in pancreatic cancer.

Peng J, Sun J, Yu Y, Yuan Q, Zhang Y Sci Rep. 2025; 15(1):52.

PMID: 39747201 PMC: 11696379. DOI: 10.1038/s41598-024-84062-3.


Exosome and lipid metabolism-related genes in pancreatic adenocarcinoma: a prognosis analysis.

Wu J, Li Y, Nabi G, Huang X, Zhang X, Wang Y Aging (Albany NY). 2023; 15(20):11331-11368.

PMID: 37857015 PMC: 10637811. DOI: 10.18632/aging.205130.


CAP2 promotes gastric cancer metastasis by mediating the interaction between tumor cells and tumor-associated macrophages.

Zhang G, Gao Z, Guo X, Ma R, Wang X, Zhou P J Clin Invest. 2023; 133(21).

PMID: 37707957 PMC: 10617780. DOI: 10.1172/JCI166224.


References
1.
Ryan D, Hong T, Bardeesy N . Pancreatic adenocarcinoma. N Engl J Med. 2014; 371(11):1039-49. DOI: 10.1056/NEJMra1404198. View

2.
Puli S, Bechtold M, Buxbaum J, Eloubeidi M . How good is endoscopic ultrasound-guided fine-needle aspiration in diagnosing the correct etiology for a solid pancreatic mass?: A meta-analysis and systematic review. Pancreas. 2012; 42(1):20-6. DOI: 10.1097/MPA.0b013e3182546e79. View

3.
Nakata K, Ohuchida K, Nagai E, Hayashi A, Miyasaka Y, Kayashima T . LMO2 is a novel predictive marker for a better prognosis in pancreatic cancer. Neoplasia. 2009; 11(7):712-9. PMC: 2697357. DOI: 10.1593/neo.09418. View

4.
Wray C, Ahmad S, Matthews J, Lowy A . Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology. 2005; 128(6):1626-41. DOI: 10.1053/j.gastro.2005.03.035. View

5.
Riley C, Engelhardt K, Saldanha J, Qi W, Cooke L, Zhu Y . Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer. Cancer Res. 2009; 69(5):1933-40. PMC: 2672909. DOI: 10.1158/0008-5472.CAN-08-2707. View